Parenteral CBD Emulsion With Omega-3 for Low-THC Pain Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing parenteral formulations of cannabidiol (CBD) suffer from high tetrahydrocannabinol (THC) content, leading to undesirable effects, and lack effective combinations with omega-3 components for treating acute and chronic pain, inflammatory, and CNS disorders.
Innovation Solution
A parenteral emulsion formulation of synthetic CBD with less than 1% THC, combined with omega-3 components such as fatty acids or triglycerides, and pharmaceutically acceptable excipients, optimized for subcutaneous, intramuscular, or intravenous administration, with globule sizes under 550 nm to minimize irritation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural CBD is used in parenteral formulations, then therapeutic effects are achieved, but high THC content causes undesirable psychological side effects
Solution Approach 1:
The patent extracts and removes THC from the CBD formulation, using synthetic CBD that contains less than 1% THC. This extraction principle eliminates the harmful psychological side effects while preserving the therapeutic benefits of CBD through selective removal of the problematic component.
Solution Approach 2:
The patent changes the chemical composition parameters by using synthetic CBD with controlled THC content below 1%, compared to natural CBD extracts that typically contain higher THC levels. This parameter change resolves the contradiction by adjusting the formulation to eliminate harmful effects while maintaining therapeutic efficacy.
2Ease of operation
If CBD is administered orally, then it is available as a solution, but high first-pass metabolism results in low bioavailability
Solution Approach 1:
The patent introduces omega-3 components as intermediary substances that form emulsion droplets to carry CBD through the digestive system and into the bloodstream. This intermediary mechanism bypasses the problematic first-pass metabolism by utilizing the lipid transport pathway, thereby improving bioavailability while maintaining the convenience of administration.
3Ease of manufacture
If parenteral formulations are prepared using conventional methods, then formulations can be made, but they require spray drying or lyophilization and reconstitution
Solution Approach 1:
The patent extracts and eliminates the need for complex processing steps like spray drying and lyophilization by formulating a stable emulsion that can be administered directly. This removal of unnecessary processing steps simplifies the manufacturing process while maintaining formulation effectiveness.
Solution Approach 2:
The patent creates a composite emulsion formulation combining CBD, omega-3 components, and other excipients in a single stable preparation that eliminates the need for reconstitution. This composite approach integrates multiple functions into one formulation, reducing processing complexity while maintaining manufacturing capability.
4Stability of the object's composition
If emulsion formulations are made with larger globule sizes, then formulation stability is improved, but irritation at injection site increases
Solution Approach 1:
The patent optimizes the globule size parameter to a specific range that balances stability and irritation. By controlling the emulsion droplet size within an optimal range, the formulation achieves adequate stability while minimizing injection site irritation, resolving the contradiction between these two parameters.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation maintains high CBD bioavailability, effectively treats acute and chronic pain, inflammation, and CNS disorders without psychological side effects, and retains stability for over a year at room temperature.
Implementation Method 1
parenteral emulsion formulations of synthetic cannabidiol comprising synthetic cannabidiol (CBD), omega 3 components and other pharmaceutically acceptable excipients
Data Source
AI summary
The present invention relates to parenteral emulsion formulations of cannabidiol comprising synthetic cannabidiol (CBD), omega 3 components and other pharmaceutically acceptable excipients. The invention further relates to parenteral emulsion formulations comprising synthetic cannabidiol in combination with one or more active agents, omega 3 components, and other pharmaceutically acceptable excipients. The formulations are used to treat acute and chronic pain, inflammatory conditions, hepatic, cardiovascular disorders, respiratory conditions, immune disorders, and CNS disorders.